| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche and Dipartimento di Biologia e Patologia Cellulare e Molecolare (G.S., M.S.), and Dipartimento di Scienze Biomorfologiche e Funzionali (A.C., I.M., G.T., L.P.), University Federico II, 80131 Napoli, Italy; Dipartimento di Oncologia (R.G., P.F., F.B.), University of Pisa, 56126 Pisa, Italy; and Department of Pathology and Laboratory Medicine and Division of Endocrinology (J.A.F., Y.E.N.), University of Cincinnati, Cincinnati, Ohio 45267
Address all correspondence and requests for reprints to: Massimo Santoro, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facoltà di Medicina e Chirurgia, University Federico II via. Sergio Pansini 5, 80131 Naples, Italy. E-mail: masantor{at}unina.it.
Point mutations in BRAF are genetic hallmarks of papillary thyroid carcinoma (PTC). In this retrospective study, we examined thyroid aspirates and corresponding paraffin-embedded surgical samples for the presence of BRAF mutations. Altogether, we examined 96 cases, including 69 PTCs, 19 follicular adenomas, and eight nontoxic nodular goiters for BRAF; 60 of these samples were also examined for RET/PTC rearrangements. The results were correlated with the cytological diagnosis and the final histopathology. The BRAF mutation (V599E) was detected in 38% of the samples that were PTC on histopathology; RET/PTC was found in 18% of the PTC cases. In all the cases, the presence of the genetic alteration was confirmed in the surgically resected tumor. The identification of BRAF mutation and RET/PTC refined the diagnosis of PTC in five of 15 samples that were considered either indeterminate or insufficient at cytology. No mutation was found in aspirates of follicular adenomas and nontoxic nodular goiters. These results indicate that BRAF mutation and RET/PTC rearrangements are molecular markers of PTC that can be applied to FNA in adjunct to traditional cytology.
This article has been cited by other articles:
![]() |
Y. E. Nikiforov, D. L. Steward, T. M. Robinson-Smith, B. R. Haugen, J. P. Klopper, Z. Zhu, J. A. Fagin, M. Falciglia, K. Weber, and M. N. Nikiforova Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2092 - 2098. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A Verburg, U. Mader, M. Luster, and C. Reiners Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases Eur. J. Endocrinol., April 1, 2009; 160(4): 619 - 624. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Alexander Approach to the Patient with a Cytologically Indeterminate Thyroid Nodule J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4175 - 4182. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Johnson and M. E. Tublin Postoperative Surveillance of Differentiated Thyroid Carcinoma: Rationale, Techniques, and Controversies Radiology, November 1, 2008; 249(2): 429 - 444. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Lin, S. D Finkelstein, B. Zhu, and J. F Silverman Molecular analysis of multifocal papillary thyroid carcinoma J. Mol. Endocrinol., October 1, 2008; 41(4): 195 - 203. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Antonelli, S. M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, I. Marchetti, C. Ugolini, F. Basolo, P. Miccoli, and E. Ferrannini Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration Eur. J. Endocrinol., September 1, 2008; 159(3): 283 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Nikiforova, G. C. Tseng, D. Steward, D. Diorio, and Y. E. Nikiforov MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1600 - 1608. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Krause, M. Eszlinger, O. Gimm, S. Karger, C. Engelhardt, H. Dralle, and D. Fuhrer TFF3-Based Candidate Gene Discrimination of Benign and Malignant Thyroid Tumors in a Region with Borderline Iodine Deficiency J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1390 - 1393. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lupi, R. Giannini, C. Ugolini, A. Proietti, P. Berti, M. Minuto, G. Materazzi, R. Elisei, M. Santoro, P. Miccoli, et al. Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4085 - 4090. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R Rowe, B. G Bentz, and J. S Bentz Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis J. Clin. Pathol., November 1, 2007; 60(11): 1211 - 1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Giannini, C. Ugolini, C. Lupi, A. Proietti, R. Elisei, G. Salvatore, P. Berti, G. Materazzi, P. Miccoli, M. Santoro, et al. The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3511 - 3516. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Eszlinger, K. Krohn, A. Kukulska, B. Jarzab, and R. Paschke Perspectives and Limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors Endocr. Rev., May 1, 2007; 28(3): 322 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhu, R. Ciampi, M. N. Nikiforova, M. Gandhi, and Y. E. Nikiforov Prevalence of RET/PTC Rearrangements in Thyroid Papillary Carcinomas: Effects of the Detection Methods and Genetic Heterogeneity J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3603 - 3610. [Abstract] [Full Text] [PDF] |
||||
![]() |
L Fugazzola, E Puxeddu, N Avenia, C Romei, V Cirello, A Cavaliere, P Faviana, D Mannavola, S Moretti, S Rossi, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr. Relat. Cancer, June 1, 2006; 13(2): 455 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Canchola, P. L. Horn-Ross, and D. M. Purdie Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer Am. J. Epidemiol., March 15, 2006; 163(6): 521 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Sapio, D. Posca, G. Troncone, G. Pettinato, L. Palombini, G. Rossi, G. Fenzi, and M. Vitale Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA) Eur. J. Endocrinol., February 1, 2006; 154(2): 341 - 348. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Xing, W. H. Westra, R. P. Tufano, Y. Cohen, E. Rosenbaum, K. J. Rhoden, K. A. Carson, V. Vasko, A. Larin, G. Tallini, et al. BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6373 - 6379. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Xing BRAF mutation in thyroid cancer Endocr. Relat. Cancer, June 1, 2005; 12(2): 245 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Saggiorato, R De Pompa, M Volante, S Cappia, F Arecco, A P Dei Tos, F Orlandi, and M Papotti Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application Endocr. Relat. Cancer, June 1, 2005; 12(2): 305 - 317. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |